

# MERCK & CO. INC.

ISIN: US58933Y1055 WKN: 58933Y105 Asset Class: **Stock**

## Company

2023/02/03 22:02:34



**Price**  
**102.94**  
USD

**Difference** **-0.50%(-0.52)**



## Contact Details

MERCK & CO. INC. Tel: 1-908-740-4000  
 -- Fax: -  
 2000 Galloping Hill Road Web: <http://www.merck.com>  
 07033 Kenilworth E-mail: -

## Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2021            |                        | 2020           |                        | 2019           |                        |
|---------------------------------------|-----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets          | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 30,266,000,000  |                        | 27,764,000,000 |                        | 27,483,000,000 |                        |
| <b>Common stock capital</b>           |                 | 1,788,000,000          |                | 1,788,000,000          |                | 1,788,000,000          |
| <b>Fixed assets</b>                   | 75,428,000,000  |                        | 63,824,000,000 |                        | 56,914,000,000 |                        |
| <b>Equity capital of a company</b>    |                 | 38,257,000,000         |                | 25,404,000,000         |                | 26,001,000,000         |
| <b>Cash and cash equivalents</b>      | 8,096,000,000   |                        | 8,062,000,000  |                        | 9,676,000,000  |                        |
| <b>Accrued liabilities</b>            |                 | 1,871,000,000          |                | 3,649,000,000          |                | 3,379,000,000          |
| <b>Other assets</b>                   | -               |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                 | 23,872,000,000         |                | 27,327,000,000         |                | 22,220,000,000         |
| <b>Prepayments and accrued income</b> | -               |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                 | 43,565,000,000         |                | 38,857,000,000         |                | 36,176,000,000         |
| <b>Different income</b>               |                 | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                 | 6,338,000,000          |                | 7,471,000,000          |                | 7,823,000,000          |
| <b>Total assets</b>                   | 105,694,000,000 | 105,694,000,000        | 91,588,000,000 | 91,588,000,000         | 84,397,000,000 | 84,397,000,000         |

## Balance notes

|                            | 2021    | 2020    | 2019    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 68,000  | 74,000  | 71,000  |
| <b>Equity ratio</b>        | 36.27%  | 27.83%  | 30.92%  |
| <b>Debt-equity ratio</b>   | 175.75% | 259.30% | 223.42% |

## Others

|                         | 2021   | 2020   | 2019   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 10.96% | 19.44% | 14.72% |

# MERCK & CO. INC.

ISIN: US58933Y1055 WKN: 58933Y105 Asset Class: **Stock**

## Income statement

|  | 2021           | 2020           | 2019           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 48,907,000,000 | 48,013,000,000 | 46,586,000,000 |
| <b>Net income</b>  | 12,345,000,000 | 7,067,000,000  | 9,843,000,000  |
| <b>EBIT</b>  | 13,302,756,900 | 8,684,160,300  | 10,972,572,300 |
| <b>Operating income before taxes</b>                                 | 13,879,000,000 | 8,791,000,000  | 11,464,000,000 |
| <b>Cash Flow</b>   | 14,109,000,000 | 10,253,000,000 | 13,440,000,000 |
| <b>Net interest income</b>   | -770,000,000   | -772,000,000   | -619,000,000   |
| <b>Research and development expenses</b>                             | 12,160,000,000 | 13,376,000,000 | 8,811,000,000  |
| <b>Income taxes</b>  | 1,521,000,000  | 1,709,000,000  | 1,687,000,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | -              | -              | -              |
| <b>Revenues per employee</b>   | 653,124        | 589,197        | 595,842        |

## Board of Directors

## Members of Management Board

|                       |                               |
|-----------------------|-------------------------------|
| Bruce Beutel          | Member of Board of Directors  |
| Christine Seidman     | Member of Board of Directors  |
| Paul Rothman          | Member of Board of Directors  |
| Risa Lavizzo-Mourey   | Member of Board of Directors  |
| Stephen Mayo          | Member of Board of Directors  |
| Douglas Baker         | Member of Board of Directors  |
| Inge Thulin           | Member of Board of Directors  |
| Kathy Warden          | Member of Board of Directors  |
| Mary Coe              | Member of Board of Directors  |
| Pamela Craig          | Member of Board of Directors  |
| Patricia Russo        | Member of Board of Directors  |
| Peter Wendell         | Member of Board of Directors  |
| Thomas Glocer         | Member of Board of Directors  |
| Robert M. Davis       | Chairman of Managing Board    |
| Dean Y. Li            | Member of Executive Committee |
| Caroline Litchfield   | Member of Executive Committee |
| Cristal N. Downing    | Member of Executive Committee |
| Dave Williams         | Member of Executive Committee |
| Frank Clyburn         | Member of Executive Committee |
| Jennifer Zachary      | Member of Executive Committee |
| Julie L. Gerberding   | Member of Executive Committee |
| Michael A. Klobuchar  | Member of Executive Committee |
| Richard R. DeLuca Jr. | Member of Executive Committee |
| Sanat Chattopadhyay   | Member of Executive Committee |
| Steven C. Mizell      | Member of Executive Committee |